Helicobacter pylori infection
Conditions
Interventions
1:Bismuth - containing standard quadruple eradication
2:Linolenic acid and polyprezinc14 days
3:Linolenic acid and polyprezinc14 days
Sponsors
Jiangsu Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-70 years male and female; 2. Patients with positive C 13 breath test and confirmed HP infection; 3. Patients treated for the first time; 4. Patients with informed consent and voluntary participation.
Exclusion criteria
Exclusion criteria: 1. Patients who have used probiotics, antibiotics, bismuth containing drugs (such as bismuth potassium citrate capsules, etc.) or histamine receptor antagonists (such as famotidine, ranitidine, cimetidine, etc.) and proton pump inhibitors (such as omeprazole, lansoprazole, pantoprazole, rabeprazole, esmesomeprazole, etc.) in the past 4 weeks; 2. Patients who are allergic to the drugs used in the treatment plan: amoxicillin, clarithromycin, esomeprazole enteric coated tablets, colloidal bismuth pectin, and polyprazin; 3. Patients with acute upper gastrointestinal bleeding, early and advanced upper gastrointestinal cancer were excluded by gastroscopy; 4. Pregnant or lactating women; 5. Patients with severe primary diseases of liver, kidney, heart, brain, lung, endocrine system and hematopoietic system that can not be effectively controlled; 6. Patients with clinical significance of liver and kidney dysfunction (transaminase is more than 1.5 times of the upper limit of normal value, or serum creatinine is greater than the upper limit of normal value); 7. Patients with malignant tumor due to mental disorder who can not give full informed consent; 8. Patients who participated in other clinical trials within three months before enrollment; 9. In addition to the above, the researcher judged the patients who were not suitable to participate in the clinical trial; according to the researcher's judgment, other situations were not suitable for joining the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C13 breath testing; | — |
Countries
China
Contacts
Public ContactZhang guoxin
Department of Gastroenterology, The First Affliated Hospital of Nanjing Medical University, Nanjing, China
Outcome results
None listed